Thoracic PROSPECT 2025 Very Severe Pain Chronic Pain Risk

Open Thoracotomy

Postoperative pain management for open thoracotomy — lobectomy, pneumonectomy, oesophagectomy, and other major open thoracic procedures. Based on PROSPECT 2025 (Lemoine et al., Anaesthesia) — a major update from the 2018 guideline.

PROSPECT 2025 ↗ ESRA ↗

Very Severe

Pain intensity

TEA = PVB

Equal first-line (2025)

~50%

Chronic pain risk

2025

PROSPECT update

Overview

Open thoracotomy is among the most painful surgical procedures performed, due to rib retraction, intercostal nerve damage, muscle division, and pleural irritation. Inadequate acute pain control impairs respiratory mechanics (shallow breathing, atelectasis, pneumonia risk) and is a major risk factor for chronic post-thoracotomy pain, which affects up to 50% of patients at 3 months and can persist for years.

📋

PROSPECT 2025 summary (Lemoine et al., Anaesthesia; 100 studies reviewed, 2015–2024): The major update from the previous guideline is that thoracic epidural analgesia (TEA) and paravertebral blockade (PVB) are now recommended equally as first-line — selection based on patient and clinician preference, not strict hierarchy. Erector spinae plane (ESP), rhomboid intercostal, or intercostal nerve blockade are second-line options when TEA/PVB cannot be performed. Basic systemic analgesia (paracetamol + NSAID/COX-2) should accompany regional technique. Acupuncture or cryoanalgesia may be considered when no regional technique is possible, albeit with low-quality evidence.

Analgesic Pathway

🕐 Pre-operative

Paracetamol 1g PO
COX-2 inhibitor or NSAID PO (if no contraindication)
Thoracic epidural placement — if planned
Patient counselling re: chronic pain risk and importance of acute control

🔪 Intra-operative

TEA infusion or single-shot/continuous PVB
Dexamethasone 8 mg IV
Paracetamol 1g IV (if not given pre-op)
Ketamine infusion — opioid-tolerant or high chronic-pain-risk patients
ESP / rhomboid intercostal / intercostal block — if TEA/PVB not feasible

💊 Post-operative

Continue TEA or PVB infusion 48–72h
Paracetamol 1g QDS regular
NSAID/COX-2 regular (≤5 days, renal function permitting)
Opioid PRN/PCA rescue
Aggressive chest physiotherapy, incentive spirometry
Cryoanalgesia — only if no regional technique possible (low evidence)

✓ Recommended | ◎ Optional/conditional | ✗ Limited evidence/last resort. Based on PROSPECT 2025 (Lemoine et al.).

Systemic Analgesia

✓ PROSPECT 2025 Recommended — Basic regimen alongside regional technique

Paracetamol + NSAID or COX-2 inhibitor should be administered postoperatively in all patients, in addition to (not instead of) the first-line regional technique. This basic systemic regimen reduces opioid requirements and supports earlier mobilisation and physiotherapy.

Agent	Dose	Route	Frequency	Notes
Paracetamol	1 g	IV/PO	QDS	Regular throughout
Celecoxib	200 mg	PO	BD	COX-2 preferred; ≤5 days; check renal function
Ibuprofen	400 mg	PO	TDS	Non-selective; consider bleeding risk post-thoracotomy
Dexamethasone	8 mg	IV	Single intraop	Analgesia + PONV prophylaxis
Ketamine	0.3–0.5 mg/kg bolus + 0.1–0.2 mg/kg/h	IV	Intra-/postop	Consider in opioid-tolerant or high chronic-pain-risk patients
Oxycodone/Morphine	Titrated	PO/IV PRN or PCA	PRN	Rescue alongside regional technique

First-Line Regional Techniques

🔑

Key 2025 update: Previous guidelines positioned thoracic epidural as the gold standard. PROSPECT 2025, after reviewing 100 studies (2015–2024), now recommends TEA and PVB equally as first-line — reflecting accumulated evidence that PVB provides comparable analgesia with a more favourable side-effect profile (less hypotension, less urinary retention, easier in anticoagulated patients).

Thoracic Epidural Analgesia (TEA)

PROSPECT ✓ First-line

Gold-standard technique historically. Bilateral coverage, excellent analgesia. Catheter placed at T4–T8 depending on incision level.

CoverageBilateral, multi-dermatomal

Key risksHypotension, urinary retention

CoagulationStrict requirements

Duration48–72h infusion

Paravertebral Block (PVB)

PROSPECT ✓ First-line

Unilateral block — avoids contralateral sympathectomy, better haemodynamic stability. Single-shot or continuous catheter. Comparable analgesia to TEA with fewer side effects.

CoverageUnilateral, multi-dermatomal

Key advantageNo contralateral sympathectomy

CoagulationMore permissive than TEA

DurationSingle-shot 10–18h; catheter 48–72h

Thoracic Epidural Analgesia (TEA)

Technique Summary

Epidural catheter sited at the thoracic level corresponding to the surgical incision (typically T4–T8 for thoracotomy), using loss-of-resistance or ultrasound-assisted landmark technique. Test dose to confirm correct placement, then maintenance infusion.

Dosing

Component	Agent	Concentration/Dose	Rate
Local anaesthetic	Ropivacaine or Bupivacaine	0.1–0.2%	5–10 mL/h infusion
+ Opioid (optional)	Fentanyl	2 mcg/mL	Combined with LA infusion
Test dose	Lidocaine 1.5% + adrenaline	3 mL	Single dose to exclude intrathecal/IV placement

⚠️

Key TEA risks to monitor: Hypotension (bilateral sympathetic block) — ensure adequate volume status, consider vasopressor support. Urinary retention — urinary catheter typically required. Motor block — monitor lower limb strength. Epidural haematoma — strict coagulation parameters required before placement and catheter removal (follow local/ASRA anticoagulation guidelines).

Paravertebral Block (PVB)

Anatomy

The thoracic paravertebral space is a wedge-shaped region lateral to the vertebral body, bounded by the parietal pleura anterolaterally, the vertebral body/intervertebral foramen medially, and the superior costotransverse ligament posteriorly. Spinal nerves emerge here before dividing into dorsal and ventral rami — local anaesthetic deposited in this space produces ipsilateral somatic and sympathetic block across multiple dermatomes due to longitudinal spread.

Technique — Ultrasound-Guided

Position & probe placement
Patient sitting, lateral, or prone (depending on timing — pre-induction or intraoperatively by surgeon under direct vision). For percutaneous US-guided approach: place probe parasagittally, 2.5–3 cm lateral to midline at the target level, identifying transverse processes and pleura.
Identify the paravertebral space
The space appears as a hypoechoic wedge between the internal intercostal membrane (superficial) and the pleura (deep), medial to the transverse process. The pleura should be seen sliding with respiration.
In-plane needle insertion
Advance the needle in-plane, aiming to pass just below the transverse process into the paravertebral space. Confirm correct placement by observing anterior displacement of the pleura with injection ("pleural depression sign").
Injection — single-shot or catheter
Inject in incremental aliquots with intermittent aspiration. For continuous technique, thread catheter 2–3 cm into the space. Volume of 0.3–0.5 mL/kg typically spreads across 4–6 dermatomes.

An intraoperative surgical approach is also well-described, where the surgeon places the catheter under direct thoracoscopic/open vision before chest closure — avoids a separate percutaneous procedure and is widely used.

Dosing

Technique	Agent	Concentration	Volume/Rate	Notes
Single-shot	Bupivacaine	0.5%	0.3–0.5 mL/kg (max 20–25 mL)	~4–6 dermatome spread
Single-shot	Ropivacaine	0.5%	20 mL	Alternative; favourable safety profile
Continuous infusion	Ropivacaine or Levobupivacaine	0.2%	5–10 mL/h	48–72h via catheter

No reports of systemic toxicity with bilateral PVB despite relatively large local anaesthetic doses — reflects slower systemic absorption from this anatomical space compared to some other compartments. Always calculate total dose against patient weight regardless.

Second-Line Regional Techniques

✓ PROSPECT 2025 — Use when TEA/PVB cannot be performed

Erector spinae plane (ESP) block, rhomboid intercostal block, or intercostal nerve blockade are recommended as second-line options — for patients with coagulopathy precluding neuraxial/paravertebral techniques, anatomical contraindications, or when local expertise favours these simpler approaches.

Technique	Coverage	Dosing	Notes
Erector spinae plane (ESP)	Multi-dermatomal, variable spread	Ropivacaine 0.3–0.4% 20–25 mL	Technically simple, good safety margin; spread less predictable than PVB
Rhomboid intercostal block	Anterolateral hemithorax	Ropivacaine 0.375% 20 mL	Newer technique; targets intercostal nerves between rhomboid and intercostal muscles
Intercostal nerve block	Segmental, per injected level	Bupivacaine 0.5% 3–5 mL per level, 3–4 levels	Often performed by surgeon intraoperatively; relatively short duration single-shot
Serratus anterior plane block	Anterolateral chest wall	Ropivacaine 0.375% 20 mL	Useful adjunct, particularly for lateral thoracotomy incisions

Chronic Post-Thoracotomy Pain

🚨

Chronic post-thoracotomy pain (CPTP) — defined as pain persisting beyond 3 months — affects up to 50% of patients and can be severely debilitating. Aggressive acute pain control is believed to reduce the risk of progression to chronic pain, making perioperative analgesic quality directly relevant to long-term outcomes, not just immediate comfort.

The recent TOPIC-2 trial — a multicentre RCT directly comparing TEA and PVB for prevention of chronic post-thoracotomy pain — addresses a question that had remained unresolved despite both techniques showing equivalent acute analgesia. This reflects ongoing research interest in identifying which first-line technique, if either, offers superior long-term outcomes.

Risk reduction strategies

Optimise acute pain control — first-line regional technique + multimodal systemic analgesia from the outset
Minimise intercostal nerve trauma — surgical technique (muscle-sparing approaches, rib-sparing retraction) reduces neuropathic injury
Consider ketamine — NMDA antagonism may reduce central sensitisation that contributes to chronification
Early identification and treatment of breakthrough neuropathic pain symptoms postoperatively
Gabapentinoids — evidence specifically for thoracotomy is mixed; not a strong PROSPECT recommendation, but may be considered case-by-case in patients with neuropathic features

Limited Evidence / Last-Resort Options

⚠ Low-Quality Evidence — Cryoanalgesia

Intraoperative cryoanalgesia (intercostal nerve freezing) is recommended by PROSPECT 2025 only when no regional analgesic technique can be performed, with the explicit caveat of low supportive evidence. Some studies raise concern about increased risk of chronic neuropathic pain with this technique.

⚠ Low-Quality Evidence — Acupuncture

Similarly positioned as a last-resort option when no regional technique is feasible. Evidence quality is low; not a substitute for first- or second-line regional analgesia when these can be safely performed.

✗ Not Supported as Primary Determinant — Surgical Technique / Physiotherapy Choice for Pain Control

PROSPECT 2025 notes that choice of surgical technique, postoperative physiotherapy regimen, and patient education approach should be based on outcomes other than pain control specifically — i.e., these factors matter for recovery generally but are not primary analgesic interventions in the PROSPECT framework.

Practical Analgesic Protocol

Suggested protocol for a typical adult patient undergoing posterolateral thoracotomy for lobectomy:

Suggested Protocol — Open Thoracotomy (Paravertebral Block)

PRE-OP

Paracetamol 1g PO · Celecoxib 200 mg PO (if renal function adequate)

INTRA-OP

GA · Paravertebral catheter (surgical placement before closure): Bupivacaine 0.5% 20 mL loading dose · Dexamethasone 8 mg IV · Paracetamol 1g IV · Consider ketamine 0.3 mg/kg bolus if high chronic pain risk

POST-OP

PVB infusion: Ropivacaine 0.2% 8 mL/h × 48–72h · Paracetamol 1g QDS regular · Celecoxib 200 mg BD (≤5 days) · Morphine PCA rescue · Aggressive chest physio + incentive spirometry from Day 0

Clinical Disclaimer Educational reference only — not medical advice. Verify all doses, coagulation requirements, and contraindications against local protocols. Individual patient assessment required by a qualified practitioner.

References

Lemoine A, et al; PROSPECT Working Group. Pain management after open thoracotomy 2025: procedure-specific postoperative pain management (PROSPECT) recommendations. Anaesthesia. 2026. DOI 10.1111/anae.70123 ↗
Joshi GP, Bonnet F, Shah R, et al. A systematic review of randomized trials evaluating regional techniques for postthoracotomy analgesia. Anesth Analg. 2008;107(3):1026–1040.
Davies RG, Myles PS, Graham JM. A comparison of the analgesic efficacy and side-effects of paravertebral vs epidural blockade for thoracotomy — a systematic review and meta-analysis of randomized trials. Br J Anaesth. 2006;96(4):418–426.
TOPIC-2 Trial Investigators. Thoracic epidural versus paravertebral blockade for reducing chronic post-thoracotomy pain (TOPIC-2): an open-label, allocation-concealed, multicentre, randomised controlled trial. medRxiv 2025. medRxiv ↗
Helms O, Mariano J, Hentz JG, et al. Intra-operative paravertebral block for postoperative analgesia in thoracotomy patients: a randomized, double-blind, placebo-controlled study. Eur J Cardiothorac Surg. 2011;40(4):902–906.
Richardson J, Lönnqvist PA. Thoracic paravertebral block. Br J Anaesth. 1998;81(2):230–238.
Steinthorsdottir KJ, Wildgaard L, Hansen HJ, Petersen RH, Wildgaard K. Regional analgesia for video-assisted thoracic surgery: a systematic review. Eur J Cardiothorac Surg. 2014;45(6):959–966.
Ülger G, Zengin M, Küçük O, et al. Comparison of combined deep and superficial serratus anterior block with thoracic paravertebral block for postoperative pain in patients undergoing VATS. Turk J Med Sci. 2024;54(5):1021–1032.